The 2025 WAO Guidelines for the classification, diagnosis, and treatment of hereditary angioedema, with consideration of worldwide disparities - PubMed
3 hours ago
- #medical guidelines
- #rare disease management
- #hereditary angioedema
- The 2025 WAO Guidelines provide a comprehensive framework for hereditary angioedema (HAE) management, emphasizing global applicability.
- HAE classification is updated: HAE-C1-INH unifies types 1 and 2; HAE-nC1-INH includes forms linked to various genetic mutations and unknown causes.
- Diagnosis focuses on early clinical recognition using characteristic features and a simplified algorithm with C1 inhibitor functional assay as the initial test.
- Management includes on-demand therapy, short-term prophylaxis, and individualized long-term prophylaxis within a treat-to-target framework for disease control.
- Guideline development involved 40 experts from 22 countries, using systematic literature review, GRADE framework adapted for rare diseases, and Delphi consensus.
- Global disparities are considered, with alternative diagnostic pathways for resource-limited settings and emphasis on patient empowerment and structured education.
- The guidelines aim for equitable, high-quality care across healthcare systems, reducing avoidable morbidity and mortality from HAE.